Diet and Exercise Recommendations for Patients Taking GLP-1 Receptor Agonists

The arrival of GLP-1 receptor agonists like semaglutide and tirzepatide has fundamentally shifted how clinicians approach weight management, making intensive behavioral therapy less essential for achieving major weight loss. Dr. Robert Kushner, a leading expert in lifestyle medicine, explains that while traditional behavioral strategies yield only 5%–8% weight loss, these medications deliver 15%–20% loss—without requiring the same level of hands-on counseling. Surprisingly, adding 30 intensive therapy visits to a semaglutide regimen only improved weight loss by 1%, suggesting that less intensive 'moderate lifestyle therapy' may be sufficient. The focus has now shifted from calorie counting to diet quality: clinicians should assess protein intake (1.2–1.5 g/kg/day), fiber, hydration, and meal patterns. High-quality protein is critical to preserve muscle mass during rapid weight loss. For side effects like nausea, patients are advised to reduce portion sizes, avoid greasy foods, stay hydrated, and time meals around medication peaks. Physical activity recommendations emphasize resistance training using accessible tools like resistance bands, even without a gym. Crucially, patients must be prepared for weight regain after stopping medication, as appetite and cravings return—making ongoing support from dietitians or healthcare providers essential for long-term maintenance.